Fulcrum Therapeutics, Inc.
26 Landsdowne Street
Cambridge, MA 02139
July 15, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Fulcrum Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-232260
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Fulcrum Therapeutics, Inc. (the Registrant) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-232260), as amended, so that it may become effective at 4:00 p.m. Eastern time on July 17, 2019, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Securities and Exchange Commission.
[Remainder of Page Intentionally Left Blank]
|
Very truly yours, | |
|
| |
|
| |
|
FULCRUM THERAPEUTICS, INC. | |
|
| |
|
By: |
/s/ Robert J. Gould |
|
|
Name: Robert J. Gould |
|
|
Title: President and Chief Executive Officer |
Signature Page to Acceleration Request